Show simple item record

dc.contributor.authorNwosu, Benjamin U.
dc.contributor.authorParajuli, Sadichchha
dc.contributor.authorKhatri, Krish
dc.contributor.authorJasmin, Gabrielle
dc.contributor.authorAl-Halbouni, Layana
dc.contributor.authorLee, Austin F
dc.date.accessioned2023-03-14T15:50:16Z
dc.date.available2023-03-14T15:50:16Z
dc.date.issued2021-11-17
dc.identifier.citationNwosu BU, Parajuli S, Khatri K, Jasmin G, Al-Halbouni L, Lee AF. Partial Clinical Remission Reduces Lipid-Based Cardiovascular Risk in Adult Patients With Type 1 Diabetes. Front Endocrinol (Lausanne). 2021 Nov 17;12:705565. doi: 10.3389/fendo.2021.705565. PMID: 34899592; PMCID: PMC8660113.en_US
dc.identifier.issn1664-2392
dc.identifier.doi10.3389/fendo.2021.705565en_US
dc.identifier.pmid34899592
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51807
dc.description.abstractImportance: Risk factors for atherosclerotic cardiovascular disease (ASCVD) are well established in type 2 diabetes (T2D), but not in type 1 diabetes (T1D). The impact of partial clinical remission (PR) on short-term ASCVD risk in T1D is unclear. Aim: To investigate the impact of PR on the earliest ASCVD risk phenotype in adult T1D using factor analysis to compare the lipid phenotypes of T1D, T2D and controls after stratifying the T1D cohort into remitters and non-remitters. Subjects and methods: A study of 203 adults subjects consisting of 86 T2D subjects, and 77 T1D subjects stratified into remitters (n=49), and non-remitters (n=28). PR was defined as insulin-dose adjusted HbA1c of ≤9, and obesity as a BMI ≥30 kg/m2. Factor analysis was used to stratify the groups by ASCVD risk by factorizing seven lipid parameters (TC, LDL, HDL, non-HDL, TC/HDL, TG, TG/HDL) into 2 orthogonal factors (factor 1: TC*LDL; factor 2: HDL*TG) that explained 90% of the variance in the original seven parameters. Results: The analysis of individual lipid parameters showed that TC/HDL was similar between the controls and remitters (p=NS) but was significantly higher in the non-remitters compared to the remitters (p=0.026). TG/HDL was equally similar between the controls and remitters (p=NS) but was lower in the remitters compared to the non-remitters (p=0.007). TG was significantly lower in the remitters compared to T2D subjects (p<0.0001) but was similar between T2D subjects and non-remitters (p=NS). Non-HDL was significantly lower in the controls versus non-remitters (p=0.0003) but was similar between the controls and remitters (p=NS). Factor analysis showed that the means of factor 1 and factor 2 composite scores for dyslipidemia increased linearly from the controls, remitters, non-remitters to T2D, p value 0.0042 for factor 1, and <0.0001 for factor 2, with remitters having similar lipid phenotype as controls, while non-remitters were similar to T2D. Conclusions: Partial clinical remission of T1D is associated with a favorable early lipid phenotype which could translate to reduced long-term CVD risk in adults.en_US
dc.language.isoenen_US
dc.relation.ispartofFrontiers in Endocrinologyen_US
dc.relation.urlhttps://doi.org/10.3389/fendo.2021.705565en_US
dc.rightsCopyright © 2021 Nwosu, Parajuli, Khatri, Jasmin, Al-Halbouni and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectadultsen_US
dc.subjectcardiovascular disease risken_US
dc.subjectdyslipidemiaen_US
dc.subjecthoneymoon phaseen_US
dc.subjectpartial clinical remissionen_US
dc.subjecttype 1 diabetesen_US
dc.subjecttype 2 diabetesen_US
dc.titlePartial Clinical Remission Reduces Lipid-Based Cardiovascular Risk in Adult Patients With Type 1 Diabetesen_US
dc.typeJournal Articleen_US
dc.source.journaltitleFrontiers in endocrinology
dc.source.volume12
dc.source.beginpage705565
dc.source.endpage
dc.source.countryUnited States
dc.source.countrySwitzerland
dc.identifier.journalFrontiers in endocrinology
refterms.dateFOA2023-03-14T15:50:17Z
dc.contributor.departmentPediatricsen_US
dc.contributor.departmentPopulation and Quantitative Health Sciencesen_US


Files in this item

Thumbnail
Name:
fendo-12-705565.pdf
Size:
1.944Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2021 Nwosu, Parajuli, Khatri, Jasmin, Al-Halbouni and Lee. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Except where otherwise noted, this item's license is described as Copyright © 2021 Nwosu, Parajuli, Khatri, Jasmin, Al-Halbouni and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.